Federal Register of Legislation - Australian Government

Primary content

PB 45 of 2011 Determinations/Health as made
This Determination amends the National Health Act 1953 - Determination under section 84AH - Exempt items (No. PB 58 of 2007) to make changes to the pharmaceutical items that are determined to be exempt.
Administered by: Health
Registered 23 Jun 2011
Tabling HistoryDate
Tabled HR04-Jul-2011
Tabled Senate04-Jul-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 45 of 2011

Amendment Determination under section 84AH of the National Health Act 1953 (2011) (No. 3)

 

National Health Act 1953

___________________________________________________________________________

 

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under section 84AH of the National Health Act 1953.

Dated   16   June 2011

 

 

 

 

 

 

 

 

 

 

 

ADRIANA PLATONA

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

 

 

 

 

 

1              Name of Instrument

 

(1)                This Instrument is the Amendment Determination under section 84AH of the National Health Act 1953 (2011) (No.3).

 

(2)                This Instrument may also be cited as PB 45 of 2011.

 

2              Commencement

                            This Instrument commences on 1 July 2011.

3              Amendments to PB 58 of 2007

                      Schedule 1 amends the legislative instrument titled Determination under section 84AH of the National Health Act 1953 (PB 58 of 2007) (as amended).

.

 


Schedule 1                   Amendments

 

      

 

[1]   Schedule 1, after entry for Clonazepam in the form Oral liquid 2.5 mg per mL, 10 mL:

            omit:

 

Clonazepam

Injection 1 mg in 1 mL and 1 mL diluent

Injection

 

          and substitute in the columns in the order indicated:

          

Clonazepam

Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)

Injection

 

 

 

[2]   Schedule 1, after entry for Cyclosporin in the form Capsule 10 mg:

          omit:

          

Cyclosporin

Solution concentrate for intravenous infusion 50 mg in 1 mL

Injection

 

         and substitute in the columns in the order indicated:

 

Cyclosporin

Solution concentrate for I.V. infusion 50 mg in 1 mL

Injection

 

     

 

[3]   Schedule 1, after entry for Digoxin:

            omit:

        

Erythromycin

Powder for intravenous infusion containing 1 g (as lactobionate)

Injection

 

            and substitute in the columns in the order indicated:

 

Erythromycin

Powder for I.V. infusion 1 g (as lactobionate)

Injection

 

 

[4]   Schedule 1, after entry for Frusemide

      omit:

 

Glyceryl trinitrate

Sublingual spray, 400 micrograms per dose

Sublingual

 

           and substitute in the columns in the order indicated:

 

Glyceryl Trinitrate

Sublingual spray (pump pack) 400 micrograms per dose, 200 doses

Sublingual

 

 

 [5]   Schedule 1, after entry for Ketoprofen

         insert in the columns in the order indicated:

Lacosamide

Oral solution 15 mg per mL, 200 mL

Oral

 

 

 

 

 

 

 

[6]   Schedule 1, after entry for Methadone in the form Injection containing methadone hydrochloride 10 mg in 1 mL

 

      omit:

 

Metronidazole

Suppository 500 mg,

Rectal

Metronidazole

Oral suspension 200 mg (as benzoate) per 5 mL, 100 mL

Oral

 

      and substitute in the columns in the order indicated:

 

Metronidazole

Suppositories 500 mg, 10

Rectal

Metronidazole

Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL

Oral

 

[7]   Schedule 1, after entry for Naproxen

 

       omit:

 

Nevirapine

Oral suspension, 10 mg per mL, 240 mL

Oral

Oestradiol

Vaginal tablet, 25 micrograms

Vaginal

 

     and substitute in the columns in the order indicated:

 

Nevirapine

Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL

Oral

Oestradiol

Vaginal tablets 25 micrograms, 15

Vaginal

 

[8]   Schedule 1, after entry for Paracetamol in the form Tablet 665 mg (modified release)

 

         omit:

 

Paracetamol

Suppository 500 mg

Rectal

Prochlorperazine

Suppository 15 mg, containing prochlorperazine maleate 25 mg

Rectal

 

        and substitute in the columns in the order indicated:

 

Paracetamol

Suppositories 500 mg, 24

Rectal

Prochlorperazine

Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5

Rectal

 

 

[9]   Schedule 1, after entry for Terbinafine

 

           omit:

 

Tipranavir

Oral solution, 100 mg per mL, 95 mL

Oral

 

           and substitute in the columns in the order indicated:

 

Tipranavir

Oral liquid 100 mg per mL, 95 mL

Oral

 

 

 

[10]   Schedule 1, after entry for Tramadol

 

         omit:

 

Valganciclovir

Powder for oral solution, 50 mg per mL, 100 mL

Oral

Valproic Acid

Crushable tablet containing sodium valproate 100 mg

Oral

 

         and substitute in the columns in the order indicated:

 

Valganciclovir

Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL

Oral

Valproic Acid

Tablet, crushable, containing sodium valproate 100 mg

Oral

 

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.